The platelet-lymphocyte ratio (PLR) is coming into use as a marker of systemic inflammation in studies on heart disease. [1] [2] [3] Cytokines play a significant role in the pathogenesis of inflammatory diseases. 4 Platelets are involved in the production of cytokines, which, in turn, contribute to platelet activation. 2 Platelets also play an active role in inflammation and the immune system. 2 As a result of changes caused by inflammation in neutrophils, platelets, and lymphocytes, the PLR has gained recognition as an inflammatory marker. 5 In an acute stress setting, lymphopenia is a common finding secondary to increased levels of corticosteroids. 2 Also, lymphopenia occurs in inflammatory states due to increased apoptosis of lymphocyte. 5, 6 The PLR has emerged as a predictor of adverse outcomes in various cardiovascular diseases. Akboga et al 7 concluded that the PLR in a control group was significantly lower than for those with mild and severe coronary artery disease (CAD). In multivariate logistic regression analysis, PLR was an independent predictor of the presence of severe CAD. Furthermore, there was a significant correlation between PLR and the severity of CAD and C-reactive protein levels.
However, Akboga et al 7 stated that all blood samples were obtained from veins and placed in tubes containing EDTA. The main limitation of this process is EDTA-dependent pseudothrombocytopenia (PTCP). EDTA-induced PTCP was first reported by Gowland et al 8 and is attributed to EDTA-induced alteration of surface glycoproteins (GP) and anionic phospholipids which enables binding of antiplatelet antibodies, which in turn cause agglutination. 8 Platelet agglutinins generally belong to the immunoglobulin M class, but immunoglobulin G and immunoglobulin A are also described. EDTA-dependent PTCP causes a false low platelet count due to EDTA-induced platelet aggregation. This condition may be caused by many factors such as clotting of blood because of insufficient anticoagulation and platelet satellitism, but most of the cases are related to thrombocyte autoagglutination along with EDTA anticoagulation. The incidence of EDTA-dependent PTCP is approximately 0.07% to 0.20% in general practice and is increased in hospitalized patients to about 0.1% to 2%. 9 Around 20% of cases with EDTA-induced PTCP also show the phenomenon in citrate anticoagulant. 10 Pseudothrombocytopenia may be a false result in a complete blood count, and it may be checked by a peripheral blood smear and citrate-anticoagulated tests. Isik et al 9 investigated the clinical and laboratory factors associated with PTCP. They reported that citrate-anticoagulated blood samples had a higher platelet count compared to the EDTA-anticoagulated sample. Another study 11 reported that EDTA-induced PTCP patients had a higher frequency of malignant tumors and a lower frequency of hypertension and diabetes mellitus than controls.
In conclusion, PLR is a novel inflammatory marker but we should keep in mind that certain diseases may affect the platelet and/or lymphocyte count, and PTCP may also occur. There is also a need to compare the PLR with other blood countderived markers of inflammation, and probably vascular risk, such as the neutrophil to lymphocyte ratio. 12 
